[Comparative evaluation of the hypoglycemic effect of the 2d-generation sulfonylurea preparations maninil and diamicron in diabetes mellitus]. 1982

M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman

Glycemia level and diurnal glucosuria were studied in the morning, afternoon and evening in a group of 27 patients with insulin-dependent diabetes mellitus before and after diamicron therapy for 1.5 to 3 months. A similar investigation was performed in a group of 20 patients, suffering from diabetes mellitus of the second type before and following maninil treatment during 1.5 to 2 months. It was shown that diamicron exerts a more pronounced sugar-lowering effect in comparison with that of maninil. It promotes stable glycemia development and should take an appropriate place among hypoglycemics used now in diabetology.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420
D005907 Gliclazide An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. Diabrezide,Diaglyk,Diaikron,Diamicron,Gen-Gliclazide,Gliklazid,Glyade,Glyclazide,Novo-Gliclazide,S-1702,S-852,Gen Gliclazide,Novo Gliclazide,S 1702,S 852,S1702,S852
D006029 Glycosuria The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1975, Problemy endokrinologii,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1993, Problemy endokrinologii,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
September 1980, Orvosi hetilap,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1966, Israel journal of medical sciences,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
November 1961, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1976, Community mental health journal,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1982, Terapevticheskii arkhiv,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
June 1989, Casopis lekaru ceskych,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
July 1978, La Clinica terapeutica,
M I Balabolkin, and T P Morozova, and S A Zhizhina, and Z I Levitskaia, and L E Gincherman
January 1987, Farmakologiia i toksikologiia,
Copied contents to your clipboard!